How LUCENTIS Is Thought to Work

Find patient-friendly information below to explain to your patients how LUCENTIS is thought to work and what they may expect with the LUCENTIS® (ranibizumab injection).

Diabetic Eye

LUCENTIS is designed to block the vascular endothelial growth factor (VEGF) that builds up in the eye with wet age-related macular degeneration. This may help reduce unhealthy swelling, leaking, and growth of blood vessels.1

Download Resource
Resources to help your patients understand what to expect from the LUCENTIS injection

Your patients may have already received a LUCENTIS treatment. If not, they should know that LUCENTIS is given as an injection into the eye.1 Feeling anxious about treatment is normal. For your patients with wet age-related macular degeneration (wet AMD), having more information about what to expect with treatment can help put them at ease.

Side effects have been seen with LUCENTIS, including serious eye infections and detached retinas.1 Before receiving injections, patients should review the Important Safety Information and see the full Prescribing Information associated with LUCENTIS.

For more information and resources for your patients to help them prepare for and stay on track with treatment, they can visit the patient LUCENTIS.com website.

wAMD Patient Brochure
wAMD Caregiver Brochure

INDICATIONS 
Wet age-related macular degeneration (wAMD)

LUCENTIS® (ranibizumab injection) is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (wAMD).

Diabetic retinopathy (DR)

LUCENTIS® (ranibizumab injection) is indicated for the treatment of patients with diabetic retinopathy (DR).

Diabetic macular edema (DME)

LUCENTIS® (ranibizumab injection) is indicated for the treatment of patients with diabetic macular edema (DME).

Macular edema following retinal vein occlusion (RVO)

LUCENTIS® (ranibizumab injection) is indicated for the treatment of patients with macular edema following retinal vein occlusion (RVO).

Myopic choroidal neovascularization (mCNV)

LUCENTIS® (ranibizumab injection) is indicated for the treatment of patients with myopic choroidal neovascularization (mCNV).

CONTRAINDICATIONS

LUCENTIS is contraindicated in patients with ocular or periocular infections or known hypersensitivity to ranibizumab or any of the excipients in LUCENTIS. Hypersensitivity reactions may manifest as severe intraocular inflammation.

WARNINGS AND PRECAUTIONS

Intravitreal injections, including those with LUCENTIS, have been associated with endophthalmitis, retinal detachment, and iatrogenic traumatic cataract. Proper aseptic injection technique should always be utilized when administering LUCENTIS. Patients should be monitored following the injection to permit early treatment, should an infection occur.

Increases in intraocular pressure (IOP) have been noted both pre-injection and post-injection (at 60 minutes) with LUCENTIS. Monitor intraocular pressure prior to and following intravitreal injection with LUCENTIS and manage appropriately.

Although there was a low rate of arterial thromboembolic events (ATEs) observed in the LUCENTIS clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).

Neovascular (wet) age-related macular degeneration

The ATE rate in the 3 controlled neovascular AMD studies during the first year was 1.9% (17 of 874) in the combined group of patients treated with 0.3 mg or 0.5 mg LUCENTIS compared with 1.1% (5 of 441) in patients from the control arms. In the second year of Studies AMD-1 and AMD-2, the ATE rate was 2.6% (19 of 721) in the combined group of LUCENTIS-treated patients compared with 2.9% (10 of 344) in patients from the control arms. In Study AMD-4, the ATE rates observed in the study during the first year were similar to rates observed in Studies AMD-1, AMD-2, and AMD-3.

In a pooled analysis of 2-year controlled studies (AMD-1, AMD-2, and a study of LUCENTIS used adjunctively with verteporfin photodynamic therapy), the stroke rate (including both ischemic and hemorrhagic stroke) was 2.7% (13 of 484) in patients treated with 0.5 mg LUCENTIS compared to 1.1% (5 of 435) in patients in the control arms (odds ratio 2.2 [95% confidence interval (0.8-7.1)]).

Macular edema following retinal vein occlusion

The ATE rate in the 2 controlled RVO studies during the first 6 months was 0.8% in both the LUCENTIS and control arms of the studies (4 of 525 in the combined group of patients treated with 0.3 mg or 0.5 mg LUCENTIS and 2 of 260 in the control arms). The stroke rate was 0.2% (1 of 525) in the combined group of LUCENTIS-treated patients compared to 0.4% (1 of 260) in the control arms.

Diabetic macular edema and Diabetic Retinopathy

In a pooled analysis of Studies DME-1 and DME-2, the ATE rate at 2 years was 7.2% (18 of 250) with 0.5 mg LUCENTIS, 5.6% (14 of 250) with 0.3 mg LUCENTIS, and 5.2% (13 of 250) with control. The stroke rate at 2 years was 3.2% (8 of 250) with 0.5 mg LUCENTIS, 1.2% (3 of 250) with 0.3 mg LUCENTIS, and 1.6% (4 of 250) with control. At 3 years, the ATE rate was 10.4% (26 of 249) with 0.5 mg LUCENTIS and 10.8% (27 of 250) with 0.3 mg LUCENTIS; the stroke rate was 4.8% (12 of 249) with 0.5 mg LUCENTIS and 2.0% (5 of 250) with 0.3 mg LUCENTIS.

Fatal events occurred more frequently in patients with DME and DR at baseline treated monthly with LUCENTIS compared with control. A pooled analysis of Studies D-1 and D-2, showed that fatalities in the first 2 years occurred in 4.4% (11 of 250) of patients treated with 0.5 mg LUCENTIS, in 2.8% (7 of 250) of patients treated with 0.3 mg LUCENTIS, and in 1.2% (3 of 250) of control patients. Over 3 years, fatalities occurred in 6.4% (16 of 249) of patients treated with 0.5 mg LUCENTIS and in 4.4% (11 of 250) of patients treated with 0.3 mg LUCENTIS. Although the rate of fatal events was low and included causes of death typical of patients with advanced diabetic complications, a potential relationship between these events and intravitreal use of VEGF inhibitors cannot be excluded.

ADVERSE EVENTS

Serious adverse events related to the injection procedure that occurred in <0.1% of intravitreal injections included endophthalmitis, rhegmatogenous retinal detachment, and iatrogenic traumatic cataract.

In the LUCENTIS Phase III clinical trials, the most common ocular side effects included conjunctival hemorrhage, eye pain, vitreous floaters, and increased intraocular pressure. The most common non-ocular side effects included nasopharyngitis, anemia, nausea, and cough.

As with all therapeutic proteins, there is the potential for an immune response in patients treated with LUCENTIS. The clinical significance of immunoreactivity to LUCENTIS is unclear at this time.

FOR ADDITIONAL SAFETY INFORMATION, PLEASE SEE LUCENTIS FULL PRESCRIBING INFORMATION.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

    • LUCENTIS [package insert]. South San Francisco, CA: Genentech, Inc; 2018.

      LUCENTIS [package insert]. South San Francisco, CA: Genentech, Inc; 2018.

    • Rosenfeld PJ, et al; MARINA Study Group. N Engl J Med. 2006;355:1419-1431.

      Rosenfeld PJ, et al; MARINA Study Group. N Engl J Med. 2006;355:1419-1431.

    • Brown DM, et al; ANCHOR Study Group. Ophthalmology. 2009;116:57-65.

      Brown DM, et al; ANCHOR Study Group. Ophthalmology. 2009;116:57-65.

    • Data on file. South San Francisco, CA: Genentech, Inc.

      Data on file. South San Francisco, CA: Genentech, Inc.

    • Busbee BG, et al; HARBOR Study Group. Ophthalmology. 2013;120:1046-1056.

      Busbee BG, et al; HARBOR Study Group. Ophthalmology. 2013;120:1046-1056.

    • Ho AC, et al; HARBOR Study Group. Ophthalmology. 2014;121:2181-2192.

      Ho AC, et al; HARBOR Study Group. Ophthalmology. 2014;121:2181-2192.

    • Sarraf D, et al. Ophthalmology. 2016;123(10):2213-2224.

      Sarraf D, et al. Ophthalmology. 2016;123(10):2213-2224.

    • Heier JS, et al; VIEW 1 and VIEW 2 Study Groups. Ophthalmology. 2012;119(12):2537-2548.

      Heier JS, et al; VIEW 1 and VIEW 2 Study Groups. Ophthalmology. 2012;119(12):2537-2548.

    • Eylea [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc; 2019.

      Eylea [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc; 2019.

    • Schmidt-Erfurth U, et al. Ophthalmology. 2014;121:193-201.

      Schmidt-Erfurth U, et al. Ophthalmology. 2014;121:193-201.